<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mrj</journal-id><journal-title-group><journal-title xml:lang="ru">Современная ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Modern Rheumatology Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1996-7012</issn><issn pub-type="epub">2310-158X</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1996-7012-2011-687</article-id><article-id custom-type="elpub" pub-id-type="custom">mrj-372</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Основные симптом-модифицирующиепрепараты замедленного действия	в терапии остеоартроза</article-title><trans-title-group xml:lang="en"><trans-title>Basic symptom-modifying delayed-action drugs in therapy of osteoporosis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бадокин</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Badokin</surname><given-names>Vladimir Vasil'evich</given-names></name></name-alternatives><email xlink:type="simple">vbadokin@yandex.ru</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бадокин</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Badokin</surname><given-names>Vladimir Vasilievich</given-names></name></name-alternatives><email xlink:type="simple">vbadokin@yandex.ru</email></contrib></contrib-group><pub-date pub-type="collection"><year>2011</year></pub-date><pub-date pub-type="epub"><day>16</day><month>09</month><year>2011</year></pub-date><volume>5</volume><issue>3</issue><issue-title>№3 (2011)</issue-title><fpage>57</fpage><lpage>63</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Бадокин В.В., Бадокин В.В., 2011</copyright-statement><copyright-year>2011</copyright-year><copyright-holder xml:lang="ru">Бадокин В.В., Бадокин В.В.</copyright-holder><copyright-holder xml:lang="en">Badokin V.V., Badokin V.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://mrj.ima-press.net/mrj/article/view/372">https://mrj.ima-press.net/mrj/article/view/372</self-uri><abstract><p>Глюкозамина сульфат или гидрохлорид, а также хондроитина сульфат - естественные компоненты хрящевого межклеточного вещества. При остеоартрозе (ОА) они оказывают выраженное симптом-модифицирующее действие и, кроме того, при длительном применении способны тормозить рентгенологическое прогрессирование ОА. Комбинированные препараты, в которые входят глюкозамин и хондроитин, имеют преимущества перед применением каждого из них в отдельности. К таким препаратам относится терафлекс. Эффективность этих фармакологических агентов, по-видимому, связана не столько со стимуляцией синтеза матрикса хряща, сколько с их антивоспалительными свойствами</p></abstract><trans-abstract xml:lang="en"><p>Glucosamine sulfate, or hydrochloride, and chondroitin sulfate are natural components of cartilaginous intercellular substance. In osteoarthrosis (OA), they exert a pronounced symptom-modifying effect and, when used long, they can also inhibit the X-ray progression of OA. The combination drugs that comprise glucosamine and chondroitin have some advantage over each component. These agents include teraflex. The efficacy of these pharmacological agents seems to be associated with their anti-inflammatory properties rather than with the stimulated synthesis of cartilaginous matrix.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>остеоартроз</kwd><kwd>хондроитина сульфат</kwd><kwd>глюкозамин</kwd><kwd>терафлекс</kwd></kwd-group><kwd-group xml:lang="en"><kwd>osteoarthrosis</kwd><kwd>chondroitin sulfate</kwd><kwd>glucosamine sulfate</kwd><kwd>teraflex</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
